Barinthus Biotherapeutics Q3 EPS $(0.21) Beats $(0.44) Estimate, Sales $14.97M

Barinthus生物製藥第三季度每股收益爲$(0.21)，超出$(0.44)的預期，銷售額爲$14.97百萬

Benzinga · 2024/11/07 00:18

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.44) by 52.27 percent. This is a 43.24 percent increase over losses of $(0.37) per share from the same period last year. The company reported $14.97 million in sales this quarter.

Barinthus Biotherapeutics (納斯達克:BRNS) 每股報告季度虧損$(0.21)，超過分析師共識預期的$(0.44)，增幅爲52.27%。這比去年同期每股虧損$(0.37)增加了43.24%。該公司本季度銷售額爲$1497萬。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

Barinthus Biotherapeutics Q3 EPS $(0.21) Beats $(0.44) Estimate, Sales $14.97M

Barinthus Biotherapeutics Q3 EPS $(0.21) Beats $(0.44) Estimate, Sales $14.97M

風險及免責聲明

聲明